Genmab — December 2016
-
Novod om Bluebird "We have previously (in our large case report on Genmab titled “Moving to the next frontier”) highlighted and discussed these issues and believe that the Genmab approach, with focus on bispecific antibodies (DuoBody) as an alternative to CAR-T, will be much more feasible, safety-wise and commercially. As a further read-across to Genmab, we see BCMA being a very interesting target in multiple myeloma and believe the data reported yesterday supports BCMA as a target.
-
Denne JNJ BCMA duobody, er den indlicenseret fra Genmab?
-
Det må være denne her https://ash.confex.com/ash/2016/webprogram/Paper91923.html
-
Her er den, men det fremgår ikke om det er en duobody fra Genmab https://ash.confex.com/ash/2016/webprogram/Paper93445.html
-
Tak Sukkeralf
-
Jeg må være halv
blind, det fremgår tydelig af teksten, at det er en Genmab duobody! -
Tak Sukkeralf, så Janssen har intet duobody som Genmab ikke er involveret i. Det er da betryggende.
-
sikke da en dag
syns mit depot er ved at se lidt anstrengt ud 
-
OHW: jamen kunne vi så ikke få det gjort her ml 16.45 - 17.00 ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind